Bluebird’s slow sickle cell launch forces rework of loan, putting cash runway at risk

Bluebird bio reported Wednesday that just four patients have started the process for receiving its sickle cell therapy Lyfgenia, endangering a $50 million loan that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

New research may pave the way for treatment of vaginal yeast infections

New research could one day pave the way for the treatment of vaginal yeast infections, by shedding new light on how microbes in the body

December 7, 2023

Tennessee gives this hospital monopoly an A grade — even when it reports failure

A Tennessee agency that is supposed to hold accountable and grade the nation’s largest state-sanctioned hospital monopoly awards full credit on dozens of quality-of-care measurements

May 29, 2024

Newron completes enrollment of schizophrenia patients in potentially pivotal study 008A with Evenamide – Biotech Investments

EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Study Newron completes enrollment of schizophrenia patients in potentially pivotal study 008A with Evenamide 29.12.2023 / 07:00 CET/CEST

December 30, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.